Return On Equity
817%
Trailing 12 months · Through 31 Mar 2026
YoY relative change: -994%
ZyVersa Therapeutics, Inc. financial metrics
Period Q1 2026 · Filed 13 May 2026
Key metrics snapshot
Return On Assets
-225%
Trailing 12 months · Through 31 Mar 2026
YoY relative change: +443%
Current Ratio
0.05x
Period-end balance · Through 31 Mar 2026
YoY relative change: -72%
NetIncomeLoss YoY
-177%
Trailing 12 months · Through 31 Mar 2026
Profitability
| Metric | Latest value | YoY relative change |
|---|---|---|
| Return On Equity |
817%
Trailing 12 months · 31 Mar 2026
|
-994% |
| Return On Assets |
-225%
Trailing 12 months · 31 Mar 2026
|
+443% |
Financial Health
| Metric | Latest value | YoY relative change |
|---|---|---|
| Current Ratio |
0.05x
Period-end balance · 31 Mar 2026
|
-72% |
Growth
| Metric | Latest value | YoY relative change |
|---|---|---|
| NetIncomeLoss YoY |
-177%
Trailing 12 months · 31 Mar 2026
|
Share Metrics
| Metric | Latest value | YoY relative change |
|---|---|---|
| Entity Common Stock, Shares Outstanding |
8,095,921
Period-end balance · 25 Mar 2026
|
+215% |
| Common Stock, Shares, Outstanding |
8,095,921
Period-end balance · 31 Mar 2026
|
+215% |
| Common Stock, Value, Issued |
$809
Period-end balance · 31 Mar 2026
|
+215% |
| Weighted Average Number of Shares Outstanding, Basic |
8,095,921
Reported period · 31 Mar 2026
|
+161% |
| Weighted Average Number of Shares Outstanding, Diluted |
8,095,921
Reported period · 31 Mar 2026
|
+161% |
Supporting Metrics
These supporting metrics stay fully source-backed for deeper research. Scan the latest value and reported period first, then open a metric page when you need the full filing trail.
| Metric | Latest value | YoY relative change |
|---|---|---|
| Accounts Payable, Current |
$10,235,276
Period-end balance · 31 Mar 2026
|
+6.6% |
| Accrued Liabilities, Current |
$3,303,242
Period-end balance · 31 Mar 2026
|
+38% |
| Additional Paid in Capital |
$125,260,381
Period-end balance · 31 Mar 2026
|
+1.8% |
| Assets |
$742,223
Period-end balance · 31 Mar 2026
|
-96% |
| Assets, Current |
$742,223
Period-end balance · 31 Mar 2026
|
-65% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
$302,660
Period-end balance · 31 Mar 2026
|
-81% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect |
$200,882
Reported period · 31 Mar 2026
|
+149% |
| Common Stock, Par or Stated Value Per Share |
0.0001
Period-end balance · 31 Mar 2026
|
0% |
| Common Stock, Shares Authorized |
250,000,000
Period-end balance · 31 Mar 2026
|
0% |
| Common Stock, Shares, Issued |
8,095,928
Period-end balance · 31 Mar 2026
|
+215% |
| Earnings Per Share, Basic |
-3.67
Trailing 12 months · 31 Mar 2026
|
+22% |
| Earnings Per Share, Diluted |
-3.67
Trailing 12 months · 31 Mar 2026
|
+22% |
| Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent |
0
Reported period · 31 Mar 2026
|
|
| General and Administrative Expense |
$5,093,064
Trailing 12 months · 31 Mar 2026
|
-27% |
| Liabilities |
$14,866,518
Period-end balance · 31 Mar 2026
|
+16% |
| Liabilities and Equity |
$742,223
Period-end balance · 31 Mar 2026
|
-96% |
| Liabilities, Current |
$14,866,518
Period-end balance · 31 Mar 2026
|
+24% |
| Net Cash Provided by (Used in) Financing Activities |
$1,000,000
Reported period · 31 Mar 2026
|
-46% |
| Net Cash Provided by (Used in) Operating Activities |
$799,118
Reported period · 31 Mar 2026
|
+55% |
| Operating Income (Loss) |
$24,652,817
Trailing 12 months · 31 Mar 2026
|
-192% |
| Preferred Stock, Par or Stated Value Per Share |
0.0001
Period-end balance · 31 Mar 2026
|
0% |
| Preferred Stock, Shares Authorized |
1,000,000
Period-end balance · 31 Mar 2026
|
0% |
| Research and Development Expense |
$911,850
Trailing 12 months · 31 Mar 2026
|
-40% |
| Retained Earnings (Accumulated Deficit) |
$139,378,318
Period-end balance · 31 Mar 2026
|
-21% |
| Share-based Payment Arrangement, Expense |
$206,412
Trailing 12 months · 31 Mar 2026
|
-63% |
| Share-based Payment Arrangement, Noncash Expense |
$55,872
Reported period · 31 Mar 2026
|
-64% |
| Stockholders' Equity Attributable to Parent |
$14,124,295
Period-end balance · 31 Mar 2026
|
-274% |
Comparisons, sources and research notes
Sources and sharing
ZVSA - ZyVersa Therapeutics, Inc. Financial Facts
- Context
- Latest metrics period: Q1 2026
- Latest reported value
- Return On Equity 817%
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open metric pages to inspect the reported history.
Tracking and update notes
Why revisit this company facts page
Company facts change as new 10-Q and 10-K filings update the latest reported period, headline values, and cross-company comparison context.
- Latest source-backed update
- Latest metrics period Q1 2026
- Why come back
- Use the next filing cycle to compare new facts against this baseline and then verify the detailed metric history.
- Current latest metrics period: Q1 2026.
- Most recent SEC facts end date on this page: 31 Mar 2026.
- Save this filer to return when the next filing-backed metric period changes the picture.
Freshness comes from the latest SEC company facts period available for this filer and the linked metric history pages.
Latest update
Latest update for ZVSA - ZyVersa Therapeutics, Inc.
Latest financial period: Q1 2026. Reopen this facts page to verify the newest reported period against the prior baseline.
Update date
13 May 2026
Page type
Company facts
Latest period
Q1 2026
SEC-backed company facts were refreshed from filings filed on 13 May 2026.
Benchmark Context
How Return On Equity compares
Return On Equity is down about 994% versus the comparable prior period.
Compared with
Compared with ZyVersa Therapeutics, Inc.'s recent history first. Same-industry peer context appears only when enough SEC-backed benchmark coverage exists.
Why this is notable
Return On Equity already has a self-history signal here, but same-industry benchmark context waits until the benchmark sample is strong enough.
- Latest comparable period on this page: Q1 2026.
- Peer context will appear when enough companies report a comparable value for this metric.
- Open the metric history first if you want to verify the exact period-to-period change.
Industry benchmark context uses SEC-reported values from the same methodology version. Latest periods may differ across companies.
How to read key metrics on this page
These short guides explain what the headline metrics mean, what to compare next, and where to open the live SEC-backed example for this company.
Plain-English Guide
How to read Net Income on this page
Net income is profit after operating costs, interest, taxes, and other non-operating items.
Why people care
It is the bottom-line profit figure many users recognize first, especially when they want to compare earnings with sales or cash flow.
How to read it
Use the same quarter or fiscal year comparison first, then check operating income or cash flow if the bottom line moved sharply.
Compare next
Compare it with operating income, EPS, and operating cash flow to see whether earnings are broad-based or driven by one-off items.
Net income can swing because of tax, financing, or accounting adjustments, so it is often less comparable than core operating metrics.
Open a live SEC-backed example
Filing notes and source
Key facts
- ZVSA - ZyVersa Therapeutics, Inc. financial facts use SEC filings; any third-party reference is labeled separately.
- Latest metrics period on this page: Q1 2026.
- Headline metric: Return On Equity 817%.
Change
- Return On Equity YoY relative change: -994%.
- Most recent SEC facts end date: 31 Mar 2026.
Research use
- This gives a beginner-friendly first read before you inspect detailed formulas and metric tables.
- Metric cards link to SEC history; a third-party reference may use a different or unverified reporting period.
Evidence
Based on latest 10-Q/10-K
View source filing
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open company facts to inspect the reported metric history.
Latest financial snapshot (2026-03-31) highlights Return On Equity 817.1%, Return On Assets -225.4%, and Current Ratio 0.05x.
Valuation Snapshot
SEC-only DCF estimate using a normalized free cash flow base, cash, debt, and reported share count when available.
No market comparison
DCF estimate is unavailable because required valuation inputs are missing.
Missing: Free cash flow.
Data confidence notes
- Free cash flow unavailable: operating cash flow or capex is missing
- Valuation unavailable: free cash flow is missing
Compare This Company Through SEC-backed Metrics
Use these links to compare ZVSA - ZyVersa Therapeutics, Inc. against other SEC filers on the same metric, then verify the company history from the paired facts page.
NetIncomeLoss YoY
Latest value: -177%
Financial Quality Score
Transparent 0-100 scoring model based on profitability, financial health, and growth factors.
33.2/100
Weak Confidence low
Return On Equity
817%
Metric score 100.0/100
Return On Assets
-225%
Metric score 0.0/100
Financial Health
- Current Ratio
- 0.05x
Strengths
Return On Equity
Watchpoints
Return On Assets, Current Ratio, and NetIncomeLoss YoY
Calculation methodology and other links
How we score
This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.
| Metric | Weight | V1 threshold |
|---|---|---|
| ROIC | 20 | 5% to 20% |
| ROE | 15 | 8% to 25% |
| ROA | 10 | 2% to 10% |
| Operating Margin | 5 | 5% to 25% |
| Current Ratio | 12 | 1.0x to 2.0x |
| Quick Ratio | 8 | 0.8x to 1.5x |
| Debt to Equity | 10 | 0.3x to 2.0x (lower is better) |
| Revenue YoY | 10 | -10% to +20% |
| Net Income YoY | 10 | -10% to +20% |
How Calculated (standard_v1)
Metrics are computed with a market-consensus convention designed for cross-portal comparability.
- Operating Income / Revenues using matching TTM or quarter periods; basis shown per metric
- Current Assets / Current Liabilities (latest instant quarter)
- (Current Assets - Inventory) / Current Liabilities; fallback: (Cash+Short-Term Investments + Accounts Receivable) / Current Liabilities
- Total Debt / Stockholders Equity (latest instant quarter; shared unit; freshest series)
- TTM Net Income / Average Equity (current quarter + same quarter previous year) / 2
- TTM Net Income / Average Assets (current quarter + same quarter previous year) / 2
- TTM NOPAT / Average Invested Capital, where NOPAT=Operating Income*(1-tax rate), Invested Capital=Equity+Total Debt-Cash & ST Investments
- Revenues YoY using available TTM or quarter comparison; basis shown per metric
- Net Income YoY using available TTM or quarter comparison; basis shown per metric
CIK / security context first